ATE504654T1 - Promotoren zur expression in modifiziertem vaccinia virus ankara - Google Patents

Promotoren zur expression in modifiziertem vaccinia virus ankara

Info

Publication number: ATE504654T1
Authority: AT; Austria
Prior art keywords: expression; vaccinia virus; promotors; virus ankara; modified vaccinia
Prior art date: 2003-11-24

Application number

AT08008470T

Other languages

English (en)

Inventor

Sonja Leyrer

Original Assignee

Bavarian Nordic As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-24

Filing date

2004-10-27

Publication date

2011-04-15

2004-10-27 Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As

2011-04-15 Application granted granted Critical

2011-04-15 Publication of ATE504654T1 publication Critical patent/ATE504654T1/de

Links

241001183012 Modified Vaccinia Ankara virus Species 0.000 title abstract 3
241000700618 Vaccinia virus Species 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Mycology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT08008470T 2003-11-24 2004-10-27 Promotoren zur expression in modifiziertem vaccinia virus ankara ATE504654T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA200301730		2003-11-24
EP04000943A EP1536015B1 (de)	2003-11-24	2004-01-17	Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara

Publications (1)

Publication Number	Publication Date
ATE504654T1 true ATE504654T1 (de)	2011-04-15

Family

ID=34442836

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
AT04000943T ATE377088T1 (de)	2003-11-24	2004-01-17	Promotoren zur expression in modifiziertem vaccinia virus ankara
AT07014231T ATE471383T1 (de)	2003-11-24	2004-01-17	Promotoren zur expression in modifiziertem vaccinia virus ankara
AT04790902T ATE420191T1 (de)	2003-11-24	2004-10-27	Promotoren zur expression im modifizierten vacciniavirus ankara
AT08008470T ATE504654T1 (de)	2003-11-24	2004-10-27	Promotoren zur expression in modifiziertem vaccinia virus ankara

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
AT04000943T ATE377088T1 (de)	2003-11-24	2004-01-17	Promotoren zur expression in modifiziertem vaccinia virus ankara
AT07014231T ATE471383T1 (de)	2003-11-24	2004-01-17	Promotoren zur expression in modifiziertem vaccinia virus ankara
AT04790902T ATE420191T1 (de)	2003-11-24	2004-10-27	Promotoren zur expression im modifizierten vacciniavirus ankara

Country Status (18)

Country	Link
US (3)	US7816508B2 (de)
EP (4)	EP1536015B1 (de)
JP (2)	JP2007512009A (de)
KR (1)	KR20060109873A (de)
CN (1)	CN1898390A (de)
AT (4)	ATE377088T1 (de)
AU (1)	AU2004295382A1 (de)
BR (1)	BRPI0416916A (de)
CA (1)	CA2546680A1 (de)
DE (4)	DE602004009743T2 (de)
DK (3)	DK1536015T3 (de)
EA (1)	EA012846B1 (de)
IL (4)	IL174653A0 (de)
NO (1)	NO20062948L (de)
NZ (1)	NZ547405A (de)
SG (2)	SG169325A1 (de)
UA (1)	UA90098C2 (de)
WO (1)	WO2005054484A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA76731C2 (uk) *	2000-11-23	2006-09-15	Баваріан Нордік А/С	Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
DK1536015T3 (da) *	2003-11-24	2008-02-18	Bavarian Nordic As	Promotorer til ekspression i modificeret vacciniavirus Ankara
EP2042604A1 (de) *	2007-09-26	2009-04-01	Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)	VV-Promotergesteuerte Überexpression von rekombinanten Antigenen
NZ592082A (en)	2008-11-27	2013-03-28	Bavarian Nordic As	Promoters for recombinant viral expression
US8613936B2 (en)	2009-03-13	2013-12-24	Bavarian Nordic A/S	Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
US8394385B2 (en) *	2009-03-13	2013-03-12	Bavarian Nordic A/S	Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
GB201006405D0 (en)	2010-04-16	2010-06-02	Isis Innovation	Poxvirus expression system
WO2012048817A2 (en)	2010-10-15	2012-04-19	Bavarian Nordic A/S	Recombinant modified vaccinia virus ankara influenza vaccine
WO2013083254A1 (en)	2011-12-09	2013-06-13	Bavarian Nordic A/S	Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
DE102013004595A1 (de)	2013-03-15	2014-09-18	Emergent Product Development Germany Gmbh	RSV-Impfstoffe
FR3042121A1 (fr)	2015-10-08	2017-04-14	Jean-Marc Limacher	Composition anti-tumorale
CN106754921A (zh) *	2016-12-12	2017-05-31	孙浩	哺乳动物细胞表达启动子及其制造和使用方法
WO2018209315A1 (en) *	2017-05-12	2018-11-15	Memorial Sloan Kettering Cancer Center	Vaccinia virus mutants useful for cancer immunotherapy
CN121443308A (zh)	2023-03-17	2026-01-30	亥姆霍兹慕尼黑中心-德国健康与环境研究中心(有限公司)	用于治疗乙型肝炎的hbv抗原制剂
WO2025172435A1 (en)	2024-02-13	2025-08-21	Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)	Hbv antigen formulation for treating hepatitis b
FR3160186A1 (fr)	2024-03-13	2025-09-19	Odimma Therapeutics	Vecteur non-viral pour transcription augmentee

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA68327C2 (en)	1995-07-04	2004-08-16	Gsf Forschungszentrum Fur Unwe	A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
DK1263936T3 (da)	2000-03-14	2006-02-13	Bavarian Nordic As	andret stamme af den modificerede Vacciniavirus Ankara (MVA)
UA76731C2 (uk) *	2000-11-23	2006-09-15	Баваріан Нордік А/С	Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
JP4554887B2 (ja) *	2001-03-08	2010-09-29	アメリカ合衆国	改変ＨＩＶエンベロープ、ｇａｇ、およびｐｏｌ遺伝子を発現するＭＶＡ
WO2003097844A1 (en)	2002-05-16	2003-11-27	Bavarian Nordic A/S	Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
WO2004015118A1 (en) *	2002-08-07	2004-02-19	Bavarian Nordic A/S	Vaccinia virus host range genes to increase the titer of avipoxviruses
DK1536015T3 (da) *	2003-11-24	2008-02-18	Bavarian Nordic As	Promotorer til ekspression i modificeret vacciniavirus Ankara

2004
- 2004-01-17 DK DK04000943T patent/DK1536015T3/da active
- 2004-01-17 EP EP04000943A patent/EP1536015B1/de not_active Expired - Lifetime
- 2004-01-17 DE DE602004009743T patent/DE602004009743T2/de not_active Expired - Lifetime
- 2004-01-17 DE DE602004027767T patent/DE602004027767D1/de not_active Expired - Lifetime
- 2004-01-17 AT AT04000943T patent/ATE377088T1/de active
- 2004-01-17 DK DK07014231.0T patent/DK1845164T3/da active
- 2004-01-17 AT AT07014231T patent/ATE471383T1/de active
- 2004-01-17 EP EP07014231A patent/EP1845164B1/de not_active Expired - Lifetime
- 2004-10-27 US US10/580,206 patent/US7816508B2/en not_active Expired - Fee Related
- 2004-10-27 EP EP08008470A patent/EP1956094B1/de not_active Expired - Lifetime
- 2004-10-27 DE DE602004032187T patent/DE602004032187D1/de not_active Expired - Lifetime
- 2004-10-27 JP JP2006540219A patent/JP2007512009A/ja active Pending
- 2004-10-27 UA UAA200607039A patent/UA90098C2/ru unknown
- 2004-10-27 SG SG201100204-5A patent/SG169325A1/en unknown
- 2004-10-27 AT AT04790902T patent/ATE420191T1/de active
- 2004-10-27 NZ NZ547405A patent/NZ547405A/en unknown
- 2004-10-27 CN CNA2004800347488A patent/CN1898390A/zh active Pending
- 2004-10-27 CA CA002546680A patent/CA2546680A1/en not_active Abandoned
- 2004-10-27 AU AU2004295382A patent/AU2004295382A1/en not_active Abandoned
- 2004-10-27 AT AT08008470T patent/ATE504654T1/de active
- 2004-10-27 KR KR1020067007781A patent/KR20060109873A/ko not_active Ceased
- 2004-10-27 DK DK04790902T patent/DK1689872T3/da active
- 2004-10-27 WO PCT/EP2004/012125 patent/WO2005054484A1/en not_active Ceased
- 2004-10-27 EP EP04790902A patent/EP1689872B1/de not_active Expired - Lifetime
- 2004-10-27 EA EA200601043A patent/EA012846B1/ru not_active IP Right Cessation
- 2004-10-27 BR BRPI0416916-6A patent/BRPI0416916A/pt not_active Application Discontinuation
- 2004-10-27 DE DE602004018975T patent/DE602004018975D1/de not_active Expired - Lifetime
- 2004-10-27 SG SG200802660-1A patent/SG142300A1/en unknown
2006
- 2006-03-30 IL IL174653A patent/IL174653A0/en not_active IP Right Cessation
- 2006-06-23 NO NO20062948A patent/NO20062948L/no not_active Application Discontinuation
2009
- 2009-06-03 IL IL199128A patent/IL199128A/en not_active IP Right Cessation
- 2009-06-03 IL IL199127A patent/IL199127A/en not_active IP Right Cessation
- 2009-06-03 IL IL199126A patent/IL199126A/en not_active IP Right Cessation
2010
- 2010-09-10 US US12/879,119 patent/US20110008792A1/en not_active Abandoned
- 2010-09-10 US US12/879,101 patent/US20110014242A1/en not_active Abandoned
- 2010-12-22 JP JP2010285881A patent/JP2011067219A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
IL199128A (en)	2011-03-31
SG142300A1 (en)	2008-05-28
EP1845164B1 (de)	2010-06-16
DK1845164T3 (da)	2010-09-20
BRPI0416916A (pt)	2007-01-23
IL199127A (en)	2010-12-30
SG169325A1 (en)	2011-03-30
NO20062948L (no)	2006-08-23
US20110014242A1 (en)	2011-01-20
EP1536015A1 (de)	2005-06-01
DK1536015T3 (da)	2008-02-18
UA90098C2 (en)	2010-04-12
ATE377088T1 (de)	2007-11-15
ATE471383T1 (de)	2010-07-15
NZ547405A (en)	2008-06-30
EP1845164A3 (de)	2008-03-19
DE602004009743D1 (de)	2007-12-13
CA2546680A1 (en)	2005-06-16
DK1689872T3 (da)	2009-04-27
WO2005054484A1 (en)	2005-06-16
EA012846B1 (ru)	2009-12-30
EP1845164A2 (de)	2007-10-17
AU2004295382A1 (en)	2005-06-16
EP1956094A1 (de)	2008-08-13
EP1689872B1 (de)	2009-01-07
DE602004027767D1 (de)	2010-07-29
EP1536015B1 (de)	2007-10-31
ATE420191T1 (de)	2009-01-15
JP2007512009A (ja)	2007-05-17
DE602004018975D1 (de)	2009-02-26
CN1898390A (zh)	2007-01-17
DE602004009743T2 (de)	2008-08-28
JP2011067219A (ja)	2011-04-07
IL174653A0 (en)	2006-08-20
EP1689872A1 (de)	2006-08-16
KR20060109873A (ko)	2006-10-23
DE602004032187D1 (de)	2011-05-19
US20110008792A1 (en)	2011-01-13
EP1956094B1 (de)	2011-04-06
IL199126A (en)	2010-12-30
US20080112971A1 (en)	2008-05-15
EA200601043A1 (ru)	2006-10-27
US7816508B2 (en)	2010-10-19

Publication	Publication Date	Title
IL199127A (en)	2010-12-30	Promoters for expression in modified vaccinia virus ankara (mva) and vectors comprising said promoters
DE60332355D1 (de)	2010-06-10	Hla-a24-restringiertes krebsantigenpeptid
NO20045480L (no)	2004-12-16	Intergeniske regioner som innskuddsseter i genomet til vacciniavirus ankara(MVA)
ATE490262T1 (de)	2010-12-15	Abschwächung der immunogenizität von fusionsproteinen
UA82998C2 (ru)	2008-06-10	Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті
DK1425404T3 (da)	2008-10-06	Vaccinia-MVA-E3L-mutanter og anvendelse deraf
ATE547519T1 (de)	2012-03-15	Gerinnungsfaktor-vii-polypeptide
IL164179A0 (en)	2005-12-18	Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
MX2022015489A (es)	2023-03-22	Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus.
CY1109244T1 (el)	2014-07-02	Νευρολοιμογονο στελεχος του ιου δυτικου νειλου και εφαρμογες αυτου.
WO2005011571A3 (en)	2006-01-05	Hepatitis virus core proteins as vaccine platforms and methods of use thereof
ATE404219T1 (de)	2008-08-15	Rekombinante poxvirus-calicivirus zusammensetzungen und anwendungen
WO2002077241A3 (en)	2003-01-30	Isolated human metalloprotease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
DE50312368D1 (de)	2010-03-11	Rekombinante mva-stamme als potentielle impfstoffe gegen p. falciparum -malaria
WO2005001096A8 (en)	2005-08-18	Vaccines against sars
DE60330140D1 (de)	2009-12-31	Gen-silencing-vektor und diesen verwendendes gen-silencing-verfahren
WO2005094415A3 (en)	2007-03-08	Recombinant vectors and methods for inducing an immune response
TH62970A (th)	2004-07-19	วัคซีนไวรัสโรคเบอร์ซาอักเสบติดต่อชนิดบรอดสเปคตรัม (broad spectrum)
ATE547530T1 (de)	2012-03-15	Rekombinante vektoren auf der grundlage des modifizierten vacciniavirus ankara (mva) als impfstoffe gegen leishmaniase